CASE REPORT
Solitary breast metastasis from oestrogen receptor-positive pulmonary adenocarcinoma: report of a case with a potential pitfall
 
More details
Hide details
 
Submission date: 2017-03-30
 
 
Final revision date: 2017-04-30
 
 
Acceptance date: 2017-05-05
 
 
Publication date: 2017-09-01
 
 
Pol J Pathol 2017;68(2):168-172
 
KEYWORDS
TOPICS
ABSTRACT
Solitary breast metastases are rare and mimic primary breast carcinoma. A 60-year-old female with a history of pulmonary adenocarcinoma presented with a solitary left breast lump suspicious for malignancy on breast imaging. Core-needle biopsy disclosed an adenocarcinoma strongly and diffusely positive for oestrogen receptors. Further immunohistochemistry was consistent with the breast tumour being a solitary metastasis of her pulmonary cancer. Clinicians and pathologists should be aware of the fact that pulmonary adenocarcinomas may sometimes display strong rather than only focal positivity for oestrogen receptors by immunohistochemistry and may mimic breast cancer of no special type.
REFERENCES (13)
1.
American Cancer Society. Cancer facts and figures 2017. Available at: https://www.cancer.org/content... (Accessed 29 March 2017).
 
2.
World Health Organization classification of tumours of the breast. Lakhani SR, Ellis IO, Schnitt SJ, et al (eds.). International Agency for Research on Cancer, Lyon 2012.
 
3.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 193: 403-410.
 
4.
Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
 
5.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology / College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
 
6.
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med 2014; 138: 241-256.
 
7.
Nieder C, Tollali T, Reigstad A, et al. Oligometastatic non-small cell lung cancer: a significant entity outside of specialized cancer centers? Med Princ Pract 2014; 23: 526-531.
 
8.
Gomez-Fernandez C, Mejias A, Walker G, et al. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem Mol Morphol 2010; 18: 137-141.
 
9.
Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-661.
 
10.
Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 402-406.
 
11.
Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of „Napsin-A” in distinguishing lung adenocarcinoma from adenocarcinoma of other organs. Appl Immunohistochem Mol Morphol 2013; 21: 191-195.
 
12.
Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012; 138: 57-64.
 
13.
Shen YW, Sui YX, Zhang XM, et al. Ipsilateral breast metastasis from a pulmonary adenocarcinoma: a case report and a focused review of the literature. Int J Clin Exp Pathol 2015; 8: 9647-9654.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top